Post

New research · Urology
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 5d
StudyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026

Expert consensus recommendations for the management of biochemical recurrence in prostate cancer: a Delphi study across clinical scenarios.

Fernando López Campos, Felipe Couñago, Juan Antonio Vallejo … Daniel Pérez Fentes
Read paper
UrologyStudy

Experts reached consensus on 75% of statements for prostate cancer recurrence management.

Expert consensus recommendations for the management of biochemical recurrence in prostate cancer: a Delphi study across clinical scenarios.

Fernando López Campos et al. · Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
Purpose

To develop expert consensus recommendations in Spain for the management of biochemical recurrence (BCR) in prostate cancer across different clinical scenarios using a modified Delphi methodology, and to provide a multidisciplinary, evidence-based framework to inform clinical decision-making regarding definition, risk stratification, imaging, and treatment after radical prostatectomy (RP), radiotherapy (RT), and RP followed by salvage RT.

Methods

A multidisciplinary scientific committee formulated 51 clinical statements based on a narrative literature review and expert experience.

n = 49 specialists
75%
Results
experts agreed on the recommendations for managing prostate cancer recurrence
n = 49 specialists
More results

Forty-two Spanish panelists completed both rounds.

The panel emphasized individualized ADT duration and risk-adapted imaging and treatment approaches.

Additional areas of ongoing debate and future research needs were identified.

“
Conclusion · 1 of 2

These expert-driven recommendations provide a structured clinical framework integrating current evidence and consensus guidance to optimize BCR management in prostate cancer.

Conclusion · 2 of 2

The findings support personalized decision-making and highlight areas requiring further prospective validation.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
HR 1.87
lower muscle quality means nearly twice the risk of dying from advanced prostate cancer
Cross-sectional
71.8%
most urologists never used a standard survey to assess stent symptoms
Cohort Study
SIR 1.67
young bladder cancer survivors have a higher risk of developing second cancers compared to the general population
Cohort Study
98%
98% of patients had no significant rectocele after laparoscopic double sacrocolpopexy.
Cohort Study
OR 0.10
Beyond 4000 J/ml, the odds of reintervention are 90% lower.
Randomized Trial
hazard ratio 0·67
pirarubicin instillation led to a lower risk of recurrence compared to observation
Study
3,216
This many specific enhancers were found in prostate cancer cells, not normal cells.
Case-control
OR = 4.23
Higher triglycerides linked to higher odds of prostate cancer (odds, not risk)